Scientists from Stanford University found drug daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder.
The research is published in The Lancet Neurology and was conducted by Emmanuel Mignot et al.
Daridorexant, sold under the brand name Quviviq, is a medication used for the treatment of insomnia.
In the study, the team assigned 930 adults with insomnia disorder to receive either daridorexant (50 mg, 25 mg) or placebo in study 1 and 924 adults to receive either daridorexant (25 mg, 10 mg) or placebo in study 2 every evening for three months.
They found that in study 1, wake time after sleep onset and latency to persistent sleep (LPS) were strongly reduced among participants in the daridorexant 50-mg group.
Similar results were seen among those receiving daridorexant 25 mg versus the placebo group.
The daridorexant 50-mg group also had strongly improved total sleep time and less insomnia daytime symptoms at month 1 and month 3.
However, the daridorexant 25-mg group only saw strong improvements in total sleep, not in insomnia symptoms.
In study 2, wake time after sleep onset was strongly reduced in the daridorexant 25-mg group at month 1 and month 3.
The daridorexant 25-mg group saw a big improvement in total sleep time at month 1 and month 3, but not in insomnia daytime symptoms.
No big improvements in any measures were seen for the daridorexant 10-mg group. The overall side effects were similar between treatment groups across studies.
The team says it is exciting to see that insomnia is finally not solely viewed as a nighttime problem but as a cause of daytime suffering.
If you care about sleep, please read studies about poor sleep linked to poor blood sugar, and if you get sleep paralysis, don’t open your eyes.
For more information about sleep, please see recent studies about how to deal with “COVID-somnia” and sleep well at night, and results showing how to sleep to prevent Alzheimer’s disease.
Copyright © 2022 Knowridge Science Report. All rights reserved.
